New MRI-Guided radiation aims to cut prostate cancer treatment time

NCT ID NCT05676463

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This phase 2 trial tested whether MRI-guided radiation therapy, given in fewer but higher doses, could safely treat high-risk prostate cancer while reducing side effects. The study enrolled 6 men with localized, high-risk prostate cancer who also received standard hormone therapy. The goal was to see if this approach could shorten overall treatment time compared to standard radiation.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
MRI-guided radiation therapy and antiandrogen therapy
What this could lead to
If successful, this approach could offer a shorter, more precise radiation treatment for high-risk prostate cancer with fewer side effects.
What could go wrong
This was a small, terminated phase 2 trial with only 6 participants, so results are very preliminary and may not apply to larger groups. The treatment still requires ongoing hormone therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.